Salim Taner Gozukizil, Halil Ibrahim Altun, Fatma Aysen Eren
Journal: Pain physician 2026;29(5):369-375
PMID: 42550529
BACKGROUND
Transforaminal epidural steroid injections (TFESIs) are a commonly used intervention for the management of lumbar radicular pain. While anatomical predictors of pain conditions like nerve compression severity, are well-known, the role of patient-specific metabolic factors has received comparatively less attention. Meanwhile, magnesium (Mg), a natural N-methyl-D-aspartate (NMDA) receptor antagonist, plays a major role in pain modulation and the prevention of central sensitization.
OBJECTIVES
To investigate the association between pre-procedural serum magnesium levels and the clinical success of TFESIs.
STUDY DESIGN
A retrospective observational cohort study.
SETTING
A tertiary referral center, Istanbul, Türkiye.
METHODS
Data from 121 patients undergoing single-level TFESIs were analyzed. The severity of each patient's radiological nerve root compression was graded using magnetic resonance imaging (MRI)-based criteria. With the use of an evidence-based cutoff value of 0.85 mmol/L to identify subclinical deficiency, the patients were categorized into groups labeled Low-Mg (< 0.85 mmol/L, n = 29) and Normal-Mg (≥ 0.85 mmol/L, n = 92). Clinical progress was tracked using the Numeric Rating Scale (NRS) and Oswestry Disability Index (ODI) at baseline, one month, and 3 months. Treatment success was defined as ≥ 50% pain relief and ≥ 40% functional improvement.
RESULTS
Despite comparable radiological nerve compression grades, patients in the low-Mg group reported significantly higher baseline pain intensity than did those in the normal-Mg group (9.65 vs. 8.15, P < 0.001). Post-procedural outcomes were significantly better in patients with normal Mg levels. Success rates differed significantly between the groups: 71.7% vs. 20.7% at one month (P < 0.001), and 66.3% vs. 34.5% at 3 months (P = 0.002). Correlation analysis suggested a possible threshold effect, with outcomes deteriorating below the defined Mg cutoff rather than following a linear dose-response relationship.
LIMITATIONS
Limitations include the study's retrospective design, the lack of dietary intake data, and the reliance on serum rather than ionized Mg measurements.
CONCLUSION
Low serum Mg levels (< 0.85 mmol/L) are associated with higher baseline pain intensity and a poor therapeutic response to TFESIs. Screening patients for their Mg levels represents a simple and potentially modifiable factor that may help improve injection outcomes, warranting consideration for supplementation in borderline cases.
Copyright: 2026, American Society of Interventional Pain Physicians.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.